Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia
ChiCTR1800015885Phase 2Recruiting
- Sponsor
- Army Medical University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Army Medical University. Primary endpoint: 1-year disease-free survival. Started May 2018; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on ChiCTR1800015885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015885.